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Management of blood pressure (BP) in patients with chronic
kidney disease receiving dialysis (stage 5D) provides a
significant challenge for healthcare professionals. The
association between BP and cardiovascular disease risk has
been well studied in the general population; however, in
dialysis patients, physiological and dialysis-related
mechanisms influencing BP are complex, and the associated
risk is poorly understood. In stage 5D, BP is determined by the
complex interplay of fluid volume and prescription of post-
dialysis target weight, sodium load, the renin–angiotensin and
sympathetic nervous systems, and diverse exogenous factors,
such as administration of erythropoiesis-stimulating agents,
the type and timing of administration of antihypertensive
drugs, and dialysate composition. Management of BP in this
population requires both generally applicable plans and
individualization in order to determine the BP target and the
treatment regimen. This report summarizes the deliberations
and recommendations of a conference sponsored by the
Kidney Disease: Improving Global Outcomes (KDIGO) to
address the following questions: (1) what is the optimal BP
treatment target in relation to end-organ damage and
outcomes in dialysis patients; (2) how should antihypertensive
drugs be used in dialysis patients; and (3) what
nonpharmacological therapies can be considered in achieving
BP targets? The conference report will augment the KDIGO
clinical practice guideline on blood pressure in chronic kidney
disease stages 1–5, which is currently under development.
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In March 2009, Kidney Disease: Improving Global Outcomes
(KDIGO) convened a Controversies Conference on Blood
Pressure in chronic kidney disease (CKD) stage 5D. The
conference, attended by 50 international experts, was
designed to review the most current information available
on the pathophysiology, epidemiology, and management of
blood pressure (BP), particularly in this population. The
plenary session presentations were followed by discussion in
small breakout groups that were asked to address three
specific issues, which the planning committee of the
conference considered to be of central importance: (1)
optimal BP in relation to end-organ damage in dialysis
patients; (2) pharmacological therapy for cardioprotection
and to achieve BP targets; and (3) nonpharmacological
therapy to achieve BP targets—focus on volume and salt
control. The breakout group deliberations were reported to
the entire group and a consensus building process led
to recommendations from the conference attendees.
The following is a report on these deliberations and
recommendations. The conference agenda, selected pre-
sentations, and abstracts of the meeting are posted on the
KDIGO website: http://www.kdigo.org/meetings_events/BP_
Controversies_Conference.php
KDIGO is an independently incorporated non-profit
organization governed by an international Board of Directors
with the stated mission to ‘improve the care and outcomes of
kidney disease patients worldwide through promoting
coordination, collaboration and integration of initiatives to
develop and implement clinical practice guidelines.’ One of
the initiatives determined by the Board of Directors of
KDIGO is a series of international conferences to examine
what is known, what can be done with what is known and
what needs to be known on controversial topics of clinical
relevance in nephrology.1
Epidemiological studies in the general population have
shown a close relationship between BP and the incidence of
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cardiovascular disease (CVD). In the past, the severity of
hypertension (HTN) was classified principally on the basis of
increased diastolic BP (DBP), which was considered to be
the best predictor of CVD risk, with increased pulse pressure
as an independent CVD risk factor in addition to DBP.
DBP generally increases from birth to the fifth decade,
followed by a decline starting at 50–60 years. The pulse
pressure increases markedly in later life, and isolated systolic
HTN becomes the predominant form of HTN after 60 years
of age in the general population. In dialysis patients,
increased systolic BP (SBP) and decreased DBP are both
associated with CVD events. Presumably, this is related to
increased arterial stiffness. In addition, decreased SBP
following previous HTN is associated with adverse out-
comes.2
Although BP is measured frequently in the dialysis
treatment environment, the technical aspects are often
unsatisfactory, with the use of poorly calibrated machines
and poor BP cuff placement on the upper arm. Recently,
quite different levels of BP in the same patients measured in
the dialysis clinic before dialysis and at home using
ambulatory BP measurements (ABPM) were shown, with
ABPM being substantially lower than dialysis clinic measure-
ments.3 A U-shaped curve relating BP to outcomes was
apparent in both sets of BP measurements, but home BP
measurements were significantly lower and more closely
associated with CVD.3
The pathophysiology of these BP patterns is complex,
implicating three principal factors: cardiac function (cardiac
output), arterial stiffness (large arteries), and intensity of
wave reflections (principally vasomotor tone of resistance
arterioles). The complex pathogenesis of HTN explains the
difficulty of its treatment. In addition, the effect of
ultrafiltration (UF) and variable plasma volume refilling
rates may frequently result in hypotensive episodes during
dialysis. The relationship of low systolic pressure with CVD
events is complex, as low SBP in some patients may represent
ideal control, but in others, it may be associated with
increased mortality.2 A practical quandary arises in the care
of an individual patient when the BP measurements are in an
apparently acceptable range, as this BP may be gradually
falling over time because of associated cardiomyopathy.
Clearly, management and outcomes are different in these
instances. Cardiac studies, and especially echocardiography,
are necessary to clarify the significance of apparently normal
BP levels. Sound BP treatment requires information on
cardiac structure and function.4,5 In addition to considera-
tion of the effect of changes in extracellular fluid volume, the
time of administration of antihypertensive drugs is also
relevant, given drug clearance during dialysis and myocardial
dysfunction.
Studies of antihypertensive medication use in dialysis
patients have been limited. In the randomized trials included
in two recent meta-analyses, the study drugs were given for
CVD management, rather than for HTN.6,7 The relative
merits of calcium channel blockers (CCBs), angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
and b-adrenergic blockers alone and in combination with
centrally acting sympatholytic agents are not satisfactorily
established. A recent review points out the powerful
relationship between aldosterone activation of aldosterone/
mineralocorticoid receptors and inflammation, resulting in
vessel wall fibrosis.8 Blockade of these receptors may be
useful, although hyperkalemia may limit their use. More
needs to be learnt about the use of drugs in conjunction with
salt restriction, volume control, and in the presence of
specific cardiovascular (CV) comorbidities, especially those
resulting in cardiac arrhythmias and sudden death. Quality-
of-life considerations with regard to side effects are
particularly relevant in dialysis patients.
In patients with low BP associated with fluid over-
load and, by necessity, low UF rates, longer dialysis treat-
ment times or more frequent dialysis could achieve normal
hydration, but this is impractical in most instances. The
patients at greatest risk are those who have low predialysis BP,
as a result of severe cardiac dysfunction.2 The prognosis of
these patients is poor, in part, because fluid can be removed
only very slowly. To further aggravate this situation, diastolic
dysfunction is often present. Even a small decrease in filling
pressure after UF may result in decreased cardiac output and
hypotension. As a result, fluid accumulates inexorably. In
addition, autonomic neuropathy complicating uremia and
diabetes, with inadequate peripheral arteriolar tone, further
increases the risk of hypotension, with the patient remaining
fluid overloaded.
The recent finding that excess sodium is stored without
osmotic activity at concentrations of 180–190mEq/l in the
skin, bound to glucosaminoglycans, could revolutionize
current views of sodium balance.9 According to this work,
the skin sodium system acts as a buffer to exogenous sodium
loading, and this sodium store can be released into the
circulation resulting in hypervolemia and oxidative stress.
This problem may be accentuated by reduction in connective
tissue mass during aging and catabolic processes, thus
decreasing the capacity of the skin to serve as a sodium
reservoir.
Although it has been established that interdialytic salt
restriction or intradialytic removal of salt and fluid volume is
effective in reducing BP, absolute success over time has been
very rare, with only the Tassin and Izmir groups consistently
being able to virtually discard antihypertensive drugs.10 In
the current three times per week dialysis regimen, each for
3–4 h, volume overload is common. Little consistent effort
has been exerted in the United States to reduce exposure to
excess sodium. Because the sodium concentration of dialysate
is usually higher than that of the patient’s serum, sodium
concentration rises during hemodialysis (HD), with the
consequence of increased thirst, extracellular volume (ECV)
expansion, and interdialytic weight gain. In addition, salt
balance is positive with habitual high dietary sodium intake
and use of saline for ‘sodium profiling’ or to maintain plasma
volume during UF.
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A further consequence of long-term hypervolemia and
an activated renin–angiotensin system is hyperactivity of the
sympathetic nervous system. Factors such as renal ischemia,
chronic inflammation, oxidative stress, obesity, nocturnal
hypoxia, and elevated plasma levels of asymmetric di-methyl-
arginine may contribute to increased sympathetic activity.
The sequelae are elevated arterial pressure, cardiac arrhyth-
mias, increased myocardial oxygen demand, and, in concert
with arterial HTN, reduced compliance of large arteries.
In addition to its volume effects, sodium exerts direct
pro-inflammatory, pro-fibrotic effects, with the potential for
aggravating kidney disease and CVD. Salt directly increases
oxidative stress and is associated with the secretion of
endogenous ouabain-like substances, such as marinobufa-
genin and endogenous ouabain. These compounds inhibit
Na/K ATPase, and may induce myocardial cell hypertrophy
in vitro. The concentration of endogenous ouabain correlates
with left ventricular mass in HD patients independent
of arterial pressure.11
The attainment of normal body hydration (‘dry weight
(DW)’), expressed in practice by recognition and attainment
of an appropriate post-dialysis weight, is difficult without
adequate means of measurement; this is a subject of much
current research.12–14 In the absence of an absolute post-
dialysis weight goal, salt restriction of all kinds is usually half-
hearted. A confounding factor is a lag between achieving
a normal extracellular fluid volume and reduction in BP.
Current public policy and societal interest in reduction of salt
intake combined with intradialytic technical solutions to
prevent accumulation of sodium during dialysis may reduce
the frequency of sodium-related HTN. Future effectiveness
studies should determine whether this will occur. Other
nonpharmacological methods to decrease BP include
nephrectomy.
Overall, the relative severity of CVD, fluctuations in
BP with every dialysis treatment, association with inflam-
mation, stimulation of vasoactive substances, activation of
mineralocorticoid receptors, increased levels of sympathetic
nervous activity, exposure to sodium loading combined
with inadequate volume control, and other factors make
management of HTN in the dialysis patient a difficult but
fascinating problem.
Guidelines on the complex problems of HTN in CKD
are being written currently. Whether the special problems
of a hypertensive dialysis patient can be addressed in clinical
practice guidelines is a relevant question, but evidence is
sparse and more clinical trials are needed.
DISCUSSION
Optimal BP target in relation to end-organ damage
in dialysis patients
How and when should BP be measured? Several options
exist, such as pre- or post-dialysis BP, ABPM, and
interdialytic home BP. Interdialytic ABPM is considered the
standard to define a patient’s BP. In the general population,
ABPM provided a more accurate prediction of CV outcomes
than office BP.15–17 In a single-center cross-sectional study,
1-week-averaged home SBP was similar to interdialytic
ABPM and superior to pre- and post-HD BP in predicting
left ventricular hypertrophy (LVH); DBP was not associated
with LVH.18 In an earlier study, ABPM added minimal
information to the prediction of LVH, compared with the
average of 12 routine pre-HD BP measurements.19
Hemodialysis BP and ABPM correlation is poor. A recent
meta-analysis showed that pre- and post-HD BP are
imprecise estimates of interdialytic ambulatory BP.20 In this
meta-analysis, median pre-HD SBP and DBP were 8.6 and
2.6mmHg higher than ABPM, respectively. A single-center
cross-sectional study showed that home BP measured by the
patients was better than pre-HD in predicting LVH. ABPM
added only weak predictive information.18 Although a
worthy goal, neither measurement of APBM nor self-
measured home BP may be feasible for most patients
throughout the world, leaving pre-HD and post-HD BP
measurements to be used, but with caution and with the
knowledge that these are inferior.
Which components of BP should be measured? Systolic BP
and DBP are associated with end-organ damage, including
vascular stiffness. Both high and low levels of either SBP
or DBP are associated with poor outcomes in dialysis
patients. A high prevalence of isolated systolic HTN exists
in the stage 5D CKD population. Clinical decisions in
managing interdialytic BP should be based on SBP and DBP,
but not on mean arterial BP.
What BP level defines HTN in chronic HD patients? As
referred to above, BP levels defining the presence or absence
of HTN differ with the use of pre-HD, post-HD, self-
measured home BP, and ABPM. The recent National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
guidelines suggest that pre-HD and post-HD BP should be
o140/90 and o130/80mmHg, respectively.4 These targets
were largely based on the expert judgment of the workgroup,
applying weak evidence. Whether the definition of HTN on
the basis of home BP should be the same as that for the
general population, as outlined in the Seventh Report of the
Joint National Committee (JNC 7),21 with SBP4139mmHg
or DBP489mmHg, can only be decided by future research.
What are treatment goals for BP in chronic HD patients?
Current data suggest that there is a ‘U-shaped’ association
between pre-HD BP and mortality. An analysis based on
the CREED study cohort adjusted for Framingham risk
factors, background CV complication, and left ventricular
mass and ejection fraction shows that the risk of death is
lowest in dialysis patients with a pre-dialysis SBP between
100 and 125mmHg,22 whereas SBP4150mmHg was
associated with increased mortality.23 Severe cardiomyopathy
modifies the relationship between BP and mortality,
and survival is very low in ESRD patients with
SBPo115mmHg.2,24 On the other hand, both post-dialysis
SBPX180mmHg and DBPX90mmHg were associated with
a substantial increase in CV mortality.22 This should be
interpreted in the light of a report of increased mortality with
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declining SBP.2 The difference in outcomes in patients with
very low and very high BP may lie in the presence of severe
cardiomyopathy in the former. In an observational study in
incident HD patients pre-HD SBPX200mmHg was asso-
ciated with increased mortality or CV events.2 Therefore,
pre-HD SBP above this level should be treated aggressively.
The BP ranges associated with the minimal risk related to the
use of self-measured home BP monitoring are currently
not known in CKD stage 5D patients. In the only study
published so far, the best outcome was observed with a self-
measured home SBP range between 120 and 145mmHg.3
Research recommendations are listed in Table 1.
Pharmacological therapy for cardioprotection
and to achieve BP targets
Special considerations for antihypertensive agents in dialysis
patients. End-stage kidney disease is associated with a 10- to
20-fold increased risk of CV mortality, compared with age-
and sex-matched controls without CKD,25 and sudden death
accounts for the majority of deaths. LVH in dialysis patients
has been convincingly attributed to fluid overload, HTN,
neuron–humoral activation, and severe anemia.26 CV risk
factors are accentuations of the risk factors observed in stage
4 and 5 CKD patients (for example, vascular medial
calcification). In addition, dialysis patients have additional
unique risk factors (for example, acute fluid and electrolyte
shifts during HD).27
Pharmacokinetics of antihypertensive and putative cardio-
protective drugs are altered by both impaired kidney
excretion of the drugs and by their dialyzability. The
multitude of drugs that these patients usually take reduces
compliance, because of tolerability, interactions with other
drugs, side effects, and financial costs.28 Pharmacotherapy to
lower BP may cause additional problems that are unique to
dialysis patients, such as intradialytic hypotension and
vascular access thrombosis.29
These patients may be more prone to side effects of certain
drugs than patients with earlier stages of CKD. The presence
of and propensity to these side effects may be easily
overlooked. For example, minoxidil may potentiate or be
confused with uremic pericardial effusion.
The evidence to guide practitioners in BP management,
CV risk factors, and CV end-organ diseases is poor.
Uncertainties in therapeutic indices of treatment strategies
that have been proven in the nondialysis population, such as
angiotensin-converting enzyme inhibitors, generate much
controversy among nephrologists caring for the dialysis
population. b-Blockers have been suggested to be cardiopro-
tective in HD in a small randomized controlled trial.30 Many
practice guidelines are largely based on low-quality evidence
and opinions.
Should vasoactive agents be used for their antihypertensive
effects or independent cardioprotective effects? Cardiac deaths
account for the majority of CV deaths in dialysis patients.
The exact etiologies of these cardiac deaths are often
unknown and likely include primary and secondary arrhy-
thmias, cardiomyopathy, and coronary artery disease, and
involve complex pathogeneses. Although fluid overload,
increased afterload from HTN and vascular calcification,
calcified valvular disease, and ischemia are probably impor-
tant contributory factors, uremia per se seems to be an
additional factor. To what extent hyperkalemia and hypoka-
lemia, frequently present in these patients, contribute to the
high incidence of sudden death in dialysis patients is not
certain, but recent papers suggested the greater danger of
hypokalemia.31,32 In addition to their antihypertensive
effects, some drugs are variably cardioprotective, which
may be independent of their BP-lowering effects. Notable
examples in this category are inhibitors of the renin–angio-
tensin–aldosterone system (RAAS), b-adrenergic blockers,
CCBs, and aldosterone inhibitors (not in HD),33 although
the real impact beyond the BP-lowering effect of some of
these agents is a matter of controversy and has been
scrutinized in a number of meta-analyses.7,34–36
Angiotensin II has been implicated in endothelial
dysfunction, smooth muscle proliferation, atherosclerotic
plaque rupture, inhibition of fibrinolysis, and ventricular
hypertrophy. Importantly, myocardial hypertrophy occurs
when angiotensin II is increased, even when BP is controlled.
Clinical studies in non-ESRD populations show that RAAS
inhibition decreases CV events in patients with left ventri-
cular dysfunction and in other high-risk individuals. Further,
RAAS inhibitors in high-risk population without overt
clinical heart failure and with stable coronary artery disease
are associated with significantly reduced risk of sudden and
arrhythmia-related deaths.37 Similarly, substantial clinical
evidence in the non-ESRD patient has shown the beneficial
effects of b-adrenergic blockers in patients with heart failure,
arrhythmia, and acute myocardial infarction.38 Moreover,
Table 1 | Research recommendations: optimal BP target in
relation to end-organ damage in dialysis patients
J Establish the relationship between self-measured home BP, ABPM,
and pre-HD BP and outcomes in diverse populations of CKD Stage 5D
patients.
J Determine the optimal frequency, timing, physical location, and
posture, including self-measured home BP measurement, and the
validation of measurement technology used.
J The mechanisms responsible for increased PP in different HD
populations should be studied, as high systolic and low diastolic
pressures frequently occur together.
J Evaluate the relationship between outcomes (morbidity and
mortality) and self-measured home BP in diverse populations of HD
patients.
J Validation of self-measured home BP followed by an RCT comparing
different home BP targets in relationship to outcomes (morbidity and
mortality).
J Assessment of the feasibility and cost-effectiveness of home BP
monitoring in the broad dialysis population would serve at least two
purposes: (1) to monitor the effect of drugs on BP during the
interdialytic interval; (2) to validate or refute the superiority of home
BP values as a predictor of hard clinical outcome.
Abbreviations: ABPM, ambulatory blood pressure measurement; BP, blood pressure;
CKD, chronic kidney disease; HD, hemodialysis; PP, pulse pressure; RCT, randomized
controlled trial.
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CCB decrease intracellular calcium levels, including those
produced by secondary hyperparathyroidism in CKD stage 5,
and alter lipid profile that may, hence, reduce CV risks.39,40
The use of RAAS inhibitors, b-adrenergic blockers, and
CCBs should be strongly considered in HD patients, as
overactivity of RAAS (increased plasma renin activity),
increased levels of sympathetic activity (elevated plasma
levels of norepinephrine and neuropeptide Y, and reduced
heart rate variability), and intracellular calcium overload are
common in dialysis patients. In particular, sympathetic
overactivity is associated with increased CV mortality in
the HD population.41–43 However, randomized trials of these
agents with hard outcomes in dialysis patients are scant. Two
recently published meta-analyses on antihypertensive medi-
cations in dialysis patients confirmed that the use of
antihypertensive medications was associated with decreases
in CV events. The analysis performed by Heerspink et al.7
included eight randomized trials (one published only in
abstract form), five of which examined RAAS blockade, two
examined b-blockers and one examined a CCB. The analysis
performed by Agarwal et al.6 included five randomized trials,
which were a subset of the eight studies examined by
Heerspink et al. In the analysis of Agarwal et al., treatment
with antihypertensive medications was associated with
decreases in CV events. However, when normotensive
subjects were included in the meta-analysis, the beneficial
effects of antihypertensive medications were markedly
diminished and became statistically non-significant, raising
the possibility that the beneficial impact of these agents is at
least partly related to their BP-lowering effect.
These meta-analyses seem to suggest a beneficial effect of
lowering BP in dialysis patients. However, there are several
caveats in this interpretation. (1) The total number of
subjects included in all eight trials examined by Heerspink
et al.7 was only 1679, with markedly heterogeneous inclusion/
exclusion criteria among the trials. For example, the trial
conducted by Cice et al.30 on b-blockers mandated a left
ventricular ejection fraction of lower than 35% in the
inclusion criteria (the actual mean left ventricular ejection
fraction of the cohort at baseline was 26%), whereas other
trials specified certain BP values for inclusion. (2) As pointed
out by Agarwal et al.,6 there seemed to be publication bias of
results in their meta-analysis, based on the Egger’s publica-
tion bias plot and the funnel plot. (3) Most importantly,
none of the trials included in either meta-analysis specifically
targeted BP levels. They were designed to examine the effects
of specific antihypertensive medications with independent
cardioprotective properties. Therefore, causality cannot be
inferred from the association between the decrease in BP and
beneficial clinical effects. A example was the trial performed
by Cice et al., which was designed to examine the effects of
carvedilol in dialysis patients with dilated cardiomyopathy
and markedly diminished ejection fractions. In this trial, the
mean BP was lower in the carvedilol group during follow-up.
Further experience using b-blockers on the incidence of
sudden death should resolve the clinical question as to the
relative importance of BP lowering in relation to cardiopro-
tective effects. In contrast, there was no difference in the BP
between the group randomized to candesartan and the
control group in the trial conducted by Takahashi et al.,44
although there was a marked decrease in the rates of CV
events and mortality in the candesartan group. Thus, the
positive effects of these drugs combine both their direct
cardioprotective and the BP-lowering effects. Nonetheless,
the beneficial clinical effects of these agents need to be
confirmed by adequately powered randomized trials with
identical BP targets in both groups. Identification of the
optimal BP target for dialysis patients would require separate
randomized trials, with different BP targets and preferably
similar agents in the randomized groups. Until such results
become available, the use of RAAS inhibitors, b-blockers, and
CCBs in dialysis patients for the purpose of decreasing
clinical hard end points can only be recommended on the
basis of studies in the general population. However, the use of
these agents in dialysis patients for compelling indications in
the general population (for example, b-blockers for heart
failure or immediately after myocardial infarction) should be
strongly considered, as it is unlikely that future large
randomized trials would include these subgroups that have
mortality risks even higher than the general dialysis
population. It should be noted that, so far none of these
putative cardioprotective agents has been shown or suggested
to increase, rather than decrease, CV risks in dialysis patients.
Which antihypertensive drugs are recommended? Recom-
mendations on antihypertensive drugs are usually based on
their efficacy in BP reduction, interdialytic and intradialytic
pharmacokinetics, side-effect profile, independent cardiopro-
tective effects (see above) and non-CV effects of the specific
class, as well as on the comorbidities of the patient.
b-Blockers are usually more effective in patients with high
normal heart rate or tachycardia than those with normal
heart rate or bradycardia. They are also indicated for patients
with angina or recent acute myocardial infarction.
a-Adrenergic blockers alleviate symptoms of prostatic
hypertrophy for those with significant residual urinary
output. Clonidine would not be the agent of choice for
patients with drowsiness. For dialysis patients with condi-
tions in which a certain drug class is considered to be
absolutely indicated in the nondialysis population (for
example, b-blockers for post-myocardial infarction), these
recommendations should still apply. Nonetheless, side
effects in a particular patient and future evidence, especially
that obtained specifically in the dialysis population, should
obviously be taken into account. Occasionally, side effects
related to the individual or HD procedure could limit the use
of specific drugs, for example, the use of a-1 blocking agents
in patients prone to intradialytic hypotension.
Aliskiren, the first in a new class of orally effective direct
renin inhibitors, was recently approved for the treatment of
HTN.45 Experience of this class of drugs in CKD stage 5 is
awaited. Consistent with its known mechanism of action,
the administration of direct renin inhibitors results in a
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reduction in both plasma renin activity and angiotensin II
concentrations. The drug is not metabolized by cytochrome
P450 enzymes, and is excreted by more than 90% unchanged
through the fecal route. No adjustments are necessary for
alterations in kidney function, age, ethnicity, or the con-
comitant administration of other drugs. It is not clear
whether the suppression of plasma renin activity results in
benefits beyond the BP-lowering effect. An argument may be
made to prescribe drugs found to be successful in patients in
the general population with CKD to the HD patients, given
the balance of risk/benefits in the former.
Beyond preferences based on the literature, guidelines in
the nondialysis population, and the use of common wisdom,
there is no compelling evidence to recommend one class of
antihypertensive agents over another. It should be noted that,
although the randomized trials included in the meta-analyses
described above examined specific drug classes, most of them
did not target specific end-organ conditions in their cohorts.
Of these, only one small trial (n¼ 114) showed a beneficial
effect of a specific b-blocker, carvedilol, on hard CV end
points. Thus, even the recommendations of specific drug
classes for CVD should be taken with caution in dialysis
patients.46–48
Considerations regarding pharmacokinetics and timing of
drug administration. Drug dialyzability has implications
beyond BP control. The removal of an antihypertensive drug
that also possesses antiarrhythmic effects (for example,
b-blocker) during HD may predispose to intradialytic
arrhythmia, especially in the presence of dialysis-induced
fluctuation in serum concentrations of electrolytes, such as
potassium and calcium.
As CCBs are not removed from the plasma during HD,
post-dialysis supplementation of these drugs is not necessary.
In contrast, the intradialytic kinetics of various angiotensin-
converting enzyme inhibitors differ significantly from each
other (Table 2). For example, although B50% of plasma
lisinopril is removed during an average HD session,
fosinopril is practically nondialyzable. Similarly, the intra-
dialytic kinetics of various b-blockers also differ from one
another. Approximately 75% of atenolol is removed by HD,
but carvedilol is practically nondialyzable.
During HD, BP decreases in B50% of the patients,
whereas an increase in BP occurs in B15% of the patients.49
BP often gradually increases during the interdialytic interval,
when the fluid gradually accumulates. The physiological
nocturnal fall in BP (nocturnal dip) is often absent in dialysis
patients. The timing, duration, severity, and etiology of
intradialytic BP changes, and if available, the behavior of BP
levels during the interdialytic period, should be considered in
the prescription of antihypertensive agents. For example,
patients with sustained HTN during the interdialytic and
intradialytic periods should take long-acting drugs. Patients
without the nocturnal dip may benefit from extra drugs
before bedtime. Some drugs should be withheld in patients
with intradialytic symptomatic hypotension before the
dialysis session, or a dialyzable drug should be used such
that its antihypertensive effect can be attenuated during
dialysis. In contrast, patients with intradialytic HTN should
avoid dialyzable drug, be supplemented with more drugs
before the dialysis session, or use other maneuvers, such as a
lower dialysate sodium concentration and higher UF rates
and volume.
Two long-acting antihypertensive drugs, atenolol and
lisinopril, have been tested for thrice-weekly administration
immediately after HD.50,51 Both agents administered in this
manner have been shown to produce sustained antihyper-
tensive effects over 44 h between dialysis sessions, without
increasing intradialytic hypotensive episodes. This method is
advantageous because the drug can be administered in the
dialysis unit under supervision, thus enhancing pharma-
coadherence.
What are the recommendations on quality-of-life issues
related to BP treatment? It is recognized that quality of life
is extremely important for dialysis patients, and that the
pharmacotherapeutic strategies may have substantial impact
on the quality of their lives. Unfortunately, there is
inadequate information to warrant specific practice recom-
mendations for this population (Table 3).
Nonpharmacological therapy to achieve BP targets—focus on
volume and salt control
The majority of patients who progress to stage 5 CKD
develop a positive sodium balance and an increase in ECV.
Salt and water overload have a central role in the
development of HTN in these patients,52 and normalizing
sodium and fluid balance is key to the control of BP and may
reduce the risk of CV events. The post-dialysis DW of a
dialysis patient may be defined as the post-dialysis body
weight at which ECV is within the normal range. As ECV is
not easily measurable, this parameter is of limited value in
clinical practice and alternative definitions have been
proposed. These include the post-dialysis body weight at
which hypotension occurs53 or at which both pre- and post-
dialysis BP are reduced to target values without the need for
antihypertensive medications.54 These definitions do not
apply to those patients who are hypotensive because of
cardiomyopathy. According to the latter definition, HTN
reflects ECV overload and BP normalization indicates
extracellular euvolemia. Most nephrologists would agree that,
at least in some patients, intradialytic HTN is undoubtedly a
manifestation of fluid overload with BP correction achieved
by fluid removal.55,56 Attempts have been made to determine
DW by bioimpedance (BIA).13,14
In clinical practice, the DW is usually established by a
progressive decrease in the post-dialysis body weight, usually
over a 4–8-week period after the initiation of maintenance
HD.57 This approach is endorsed by the Dry weight
Reduction In hypertensive HD Patients (DRIP) study, in
which a significant decrease of the pre-dialysis SBP was
achieved after 4 weeks in a group of patients randomized to a
1.1% body weight reduction, as compared with those in
whom no active intervention took place.58 Unfortunately,
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Table 2 | Antihypertensive drugs, excretion pathway, dosage, and supplement in CKD and chronic dialysis
Removal with dialysis
Supplement
Usual dose Excretion GFRo10ml/min Hemodialysis Peritoneal dialysis for dialysis
Diuretics
Acetazolamide 250mg q6–8h K Avoid Unknown Unknown Not applicable
Amiloride 5–10mg q.d. K Avoid N/A N/A Not applicable
Bumentanide 0.5–2mg q8–12 h K 100% None None None
Chlorthalidone 30–60mg q.d. K Avoid N/A N/A Not applicable
Ethacrynic acid 50–100mg b.i.d. L (K) Avoid None None Not applicable
Furosemide 40–80mg b.i.d. K (L) 100% None None None
Hydrochlorothiazide 25–50mg q.d. K Avoid None None Not applicable
Indapamide 2.5mg q.d. K Avoid None None Not applicable
Metolazone 5–10mg q.d. K (L) 100% None None None
Spironolactone 50–100mg q.d./b.i.d. K (L) Avoid N/A N/A Not applicable
Torsemide 5–10mg b.i.d. L (K) 100% Avoid Avoid None
Trimaterene 25–50mg b.i.d. K Avoid N/A N/A Not applicable
b-blockers
Acebutolol 400–600mg q.d./b.i.d. L (K) 30–50% 30% None 150mg
Atenolol 50–100mg q.d. K (L) 25–50% 50% None 25–50mg
Betaxolol 10–20mg q.d. L 50% None None None
Bisoprolol 2.5–20mg q.d. L 100% None None None
Carvedilol 25 mg b.i.d. L (K) 50% None Unknown None
Esmolol 50–150mg/kg/min i.v. L 100% None None None
Labetalol 200–600mg b.i.d. K (L) 100% None None None
Metoprolol 50–100mg b.i.d. K (L) 100% None None 50mg
Nadolol 80–100mg b.i.d. K 25% 50% None 80mg
Pindolol 10–40mg b.i.d. K (L) 100% None None None
Propanolol 80–160mg b.i.d. K 100% None None None
Sotalol 160mg q.d. K 15–30% 50% None 50mg
Timolol 10–20mg b.i.d. L (K) 100% None None None
CCB
Amlodipine 2.5–10mg q.d. L 100% None None None
Diltiazem CD 180–360mg L (K) 100% None None None
Felodipine 5–10mg q.d. L 100% None None None
Isradipine 2.5–10mg b.i.d. L 100% None None None
Lacidipine 2–6mg/day L (K) 100% None None None
Manidipine 10–20mg/day L 100% None None None
Nicardipine 20–40mg t.i.d. L 100% None None None
Nifedipine XL 30–90mg q.d. L 100% None None None
Nimodipine 30mg q8 h K (L) 100% None None None
Nisoldipine 10mg b.i.d. K (L) 100% None None None
Nitrendipine 20mg b.i.d. L (K) 100% None None None
Verapamil CD 180–360mg q.d. L 100% None None None
ACEi
Benazapril 5–40mg q.d. K (L) 50–75% Negligible None 5–10mg
Captopril 12.5–50mg t.i.d. K 50% 50% None 12.5–25mg
Enalapril 2.5–10mg q12h K (L) 50% 50% None 2.5–5mg
Fosinopril 10mg q.d. K (L) 75% None None None
Lisinopril 2.5–10mg q.d. K 25–50% 50% None 2.5–5mg
Perindopril 2–8mg/day K (L) 25–50% 50% None 2mg
Quinapril 10–20mg q.d. K (L) 50% 25% None 10mg
Ramipril 5–10mg q.d. K (L) 25–50% 20% None 2.5mg
Trandolapril 0.5–4mg/day K (L) 25–50% 30% None 0.5mg
ARB
Candesartan 8–35mg/day K (L) 100% None None None
Eprosartan 600–1200mg/day L 100% None None None
Ibersartan 75–300mg/day L 100% None None None
Losartan 50–100mg q.d. K (L) 100% None None None
Olmesartan 10–40mg/day K (L) 100% None None None
Telmisartan 40–80mg/day L 100% None None None
Valsartan 80–320mg q.d. L (K) 100% None None None
DIR
Aliskiren 150–300mg q.d. K Unknown Unknown Unknown Unknown
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target weight reduction to normalize BP may increase the
frequency of intradialytic hypotension,59 which in turn may
damage the heart,60 and is associated with increased
mortality.61 That the same phenomena can occur in the
severely over-hydrated patient, favors the achievement of a
post-dialysis ‘target weight’ in some patients, which might be
higher than the DW as a clinically practical alternative. The
requirement for a difference between the DW and target
weight illustrates the dilemma faced by the healthcare
professional in avoiding intradialytic BP decreases while
attempting to optimize DW in an effort to correct high BP.
However, longer dialysis time periods and methods to reduce
interdialytic weight gain attenuate the occurrence of
hypotension. In attempting to achieve ‘target weight’,
particularly in incident patients starting dialysis, clinicians
should be mindful also of the lag in time (from several weeks
to months) between correction of ECV and HTN.62 Similar
principles apply to patients receiving peritoneal dialysis, in
whom salt and water removal is influenced by dialysis fluid
sodium concentration and choice of dialysis technique.
How should ECV and DW be measured? The history and
physical examination may be helpful in detecting more
obvious ECV increases. For example, clinical assessment of
internal jugular venous pressure provides information
Table 2 | Continued
Removal with dialysis
Supplement
Usual dose Excretion GFRo10ml/min Hemodialysis Peritoneal dialysis for dialysis
Central a-agonists
Clonidine 0.1–0.3mg b.i.d./t.i.d. K (L) 100% 5% None None
Guanabenz 8–16mg b.i.d. L 100% None None None
Guanethidine 10–100mg q.d. K (L) 50% (avoid) None None None
Methyldopa 250–500mg b.i.d./t.i.d. K (L) q12–24 h 60% 30–40% 250–500mg
Reserpine 0.05–0.25mg q.d. L Avoid None None None
a1-blockers
Doxazosin 1–16mg q.d. L 100% None None None
Prazosin 1–15mg b.i.d. L 100% None None None
Terazosin 1–20mg q.d. L 100% None None None
Vasodilators
Diazoxide 150–300mg bolus L 100% None None None
Hydralazine 25–50mg t.i.d./q.i.d. L q8–16 h 25–40% 25–40% None
Minoxidil 5–30mg b.i.d. L 100% None None None
Nitroprusside 0.25–0.8mg/kg/min i.v. L (K) 100% None None None
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; CKD, chronic kidney disease; DIR, direct
inhibitors of renin; GFR, glomerular filtration rate; i.v., intravenous; K, kidney; L, liver; N/A, not applicable.
Table 3 | Research recommendations: pharmacological therapy for cardioprotection and to achieve BP targets
J Examination of the pharmacokinetics, pharmacodynamics, and optimal frequency of administration of anti-hypertensive drugs in various dialysis
populations (for example, defined by degrees of residual kidney function) and various dialytic modalities (conventional thrice-weekly HD, low-flux
versus high-flux HD, short daily HD, nocturnal HD, hemofiltration, and peritoneal dialysis).
J Optimization of the choice (for example, long-acting versus short-acting, dialyzable versus non-dialyzable), dosing schedule, and intensity of anti-
hypertensive drugs, with BP levels (not hard end points) as targets, recognizing that the optimal BP level needs to be defined in separate trials.
Investigation of the effectiveness of these drugs in reducing BP in patients with fluid overload.
J Determination of any circumstances when drugs, instead of fluid volume contraction, should be the first-line strategy to lower BP; this would be
appropriate when patients had reached their dry weight.
J Examination of the side-effects of anti-hypertensive drugs (for example, hyperkalemia with RAAS blockade, leg edema and pericardial effusion with
minoxidil, cardiac and neurological effects of the combination of b-blockers and central-acting sympatholytic agents, and effects of drugs on the
prolonged QT interval on electrocardiogram, which is associated with increased risks of sudden cardiac death), the prevalence of these side-effects
in dialysis patients and interactions of anti-hypertensive drugs with the dialysis procedure (for example, does it counteract the arrhythmogenicity of
acute changes in serum potassium and calcium concentrations).
J Large definitive randomized trial of putative cardioprotective drugs (for example, RAAS inhibitors and b-blockers) in the general dialysis population,
independent of BP targets. Successful cardioprotective drugs may constitute the background treatment to which further anti-hypertensive drugs
can be added to manage HTN.
J Development and validation of instruments to evaluate quality of life associated with pharmacotherapy used for BP management in the dialysis
population. Validation in various countries would reveal how their respective cultures might modulate patients’ quality of life related to the BP
treatment and its manifestations.
J Examination of drugs (for example, RAAS blockade) on sleep apnea, which is a risk factor for both HTN and cardiovascular events.
Abbreviations: BP, blood pressure; HD, hemodialysis; HTN, hypertension; RAAS, renin–angiotensin–aldosterone system.
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concerning right atrial pressure and volume increase. Ankle
edema is frequently associated with increased ECV, but its
specificity is low.63 In general, assessment of DW using such
clinical parameters lacks sensitivity.64 Many hypertensive
dialysis patients may not show the physical signs of
intravascular or interstitial fluid overload despite several
liters increase in their ECV, although a progressive decrease in
the target weight corrects their HTN.55
Subclinical ECV overload may be assessed using BIA
analysis. Essig et al.65 used a multifrequency BIA device in the
early stages of CKD to describe an association between
increased ECV and CV remodeling. In dialysis patients,
intradialytic measurement of BIA may be helpful in the
assessment of DW. By monitoring regional resistance and
resistivity in the calf, Zhu et al.14 showed that it was possible
to decrease the prescribed ‘target weight’ with associated BP
decrease over time to approach DW in prevalent HD patients.
Other BIA devices that assess whole body composition13
provide readouts of BP and ECV status that may be useful
in longitudinal follow-up of fluid balance. Using a whole
body approach to measure BIA, a recent study showed that
dialysis patients with a 15% or greater ECV increase
over normal displayed an increased risk of mortality.66
Other methods of assessing ECV include measurement of
vena cava diameter (to assess intravascular volume), which
requires time for equilibration at the end of the dialysis
session and is operator dependent.67 Cardiac peptides, such
as brain natriuretic peptide, are associated with mortality in
dialysis patients68,69 and high plasma levels are associated
with volume overload.70 However, their use as an ECV
overload indicator is confounded by cardiac disease, the
influence of intradialytic removal of the peptide, and fistula
blood flow.70 Methods of assessing intradialytic blood
volume change have been useful in the context of prescrip-
tion of UF rate, but are not valuable to accurately determine
fluid overload.
What is the role of sodium balance? During the dialysis
session, ECV overload is largely corrected by the process of
convection. However, the prescribed dialysate sodium concen-
tration may significantly influence sodium flux by diffusive
transport. Increasing the dialysate sodium concentration
above the individual patient’s own pre-dialysis serum value
may reduce intradialytic adverse effects, such as hypo-
tension,71 but may lead to increased weight gain (IDWG)
driven by thirst.72 Using BIA, Sarkar et al.73 have shown
that a high gradient can induce intracellular shrinking by
as much as 2.5 l. It may therefore be best to adjust sodium
dialysate concentration to match the patient’s pre-dialysis
plasma sodium and not use higher dialysate sodium
concentrations. Such individualization of sodium dialysate
concentration leads to a decreased IDWG, thirst score,
intradialytic hypotension episodes, and lower BP in hyper-
tensive patients, compared with a fixed sodium dialysate
concentration (138mmoles/l).74 More conveniently, the
sodium concentration in dialysate might be determined
from plasma conductivity measured by the dialysis machine,
but this approach is problematic because of the different
sodium conductivity relationships pre- and post-dialysis.72,75
The benefits of ‘sodium profiling’ with or without feedback
control in an effort to maintain neutral sodium balance are
unclear,75–77 but certainly are another reason for sodium
overload. Use of hypertonic dextrose rather than saline in the
management of intradialytic hypotension and cramps also
increases the potential for a neutral sodium balance.
Should dietary sodium be restricted? According to the
World Health Organization, there is sufficient evidence to
recommend a low salt diet (5 g/day) to the general
population, because a large salt intake is associated with
increased BP and CVDs. Dietary salt restriction was useful in
the quest for optimization of DW to obtain BP control in the
‘Tassin experience’.78 Recently, Kayikcioglu et al.79 have
compared a group of 190 HD patients restricted to a 5-g
salt diet with a control group in a cross-sectional study of 204
HD patients with free salt intake. The BP was similar in the
two groups, but with only 7% of patients in the low salt
intake group versus 42% of the free salt intake group
requiring antihypertensive drugs. Furthermore, the IDWG
was lower in the salt-restricted group (2.29±0.83 kg versus
3.31±1.12 kg) with fewer episodes of intradialytic hypo-
tension, and reduction in left ventricular mass was greater
in the salt-restricted group. Interventional studies assessing
salt restriction have consistently reported a decrease in
IDWG during salt restriction80–83 with an associated decrease
in BP.80–82,84–86
What is the role of longer or more frequent dialysis? A high
UF rate enhances the risk of muscle cramps and hypotensive
episodes. The treatment for such complications includes
reducing the UF rate and administering intravenous saline,
Table 4 | Research recommendations: non-pharmacological therapy to achieve target BP focus on volume and salt control
J A descriptive longitudinal study characterizing the relationship between pre- and post-dialysis serum sodium concentration, ECV (measured using
the bioimpedance techniques) and BP is required with long-term follow-up of clinical outcomes to identify high-risk patient groups and to facilitate
the future design of RCTs.
J An RCT of different dietary sodium intakes and dialysate–plasma sodium gradients is required in hypertensive HD patients to study impact on BP and
of both intradialytic and interdialytic weight gain.
J An RCT of antihypertensive drugs with and without sodium restriction, for example in a 2 2 factorial design.
J An RCT randomizing patient to two different ECV targets is required in HD patients with outcomes that include surrogate hemodynamic parameters
and clinical outcomes.
J Longitudinal studies are required to assess the value of plasma brain natriuretic peptide level measurements during fluid removal in incident HD
patients.
Abbreviations: BP, blood pressure; ECV, extracellular volume; HD, hemodialysis; RCT, randomized controlled trial.
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which undermines the aims of the original intervention and
may result in an expanded ECV at the end of treatment. Such
corrective maneuvers thus prevent achievement of the
prescribed target weight,87 and create the conditions for
perpetuation of HTN and the risk of LVH and cardiac
failure.88 These problems are illustrated by data from the
DOPPS cohort study in which an independent increase of
mortality risk was noted in patients with an UF rate over
10ml/kg/hour.61 In these patients, the risk of intradialytic
hypotension was increased by 30%. In another prospec-
tive study with a 5-year follow-up,89 an UF rate of over
12.7ml/kg/hour was an independent risk factor for mortality.
These high UF rates may reflect excess of salt and fluid intake.
The prescription of longer and/or more frequent dialysis
sessions allows the decrease in UF rate and reduces the risk of
intradialytic complications.90–92 This has been shown by a
number of studies in which alternative dialysis methods such as
short daily, long daily, and long conventional HD improve
LVH,93–96 sympathetic overactivity, and/or vascular reactiv-
ity97–100 and improve ejection fraction in patients with heart
failure.101,102 Research recommendations are shown in Table 4.
CONCLUSIONS
Hypertension is an ubiquitous finding in HD patients with
major implications for survival. Accurate measure of BP is an
essential precursor for management. As pre-HD BP measure-
ment may not reflect the average BP experienced by the
patient, the question of how and where the measurements
should be made is of importance. At present, the evidence for
the superiority of self-measured BP at home over pre-HD BP
is impressive. Attainment of BP targets in keeping with experi-
ence in non-HD patients are practicable, but the modifying
effect of cardiomyopathy in hypertensive patients resulting in
declines of BP (to those targets) make it difficult without further
cardiac investigation to distinguish patients with a satisfactory
target BP from those with severe cardiac disease. Use of echo-
cardiography is essential to understand this problem.
In general, all antihypertensive drugs can be used in the
HD population with doses determined by dialyzability and
hemodynamic instability. However, the concomitant cardio-
protective effects of these drugs need to be considered when
assessing outcomes, in light of the current scanty evidence. It
could be argued that any established use of these drugs in the
general population should probably be widely applied to HD
patients as long as no firm evidence is available in this specific
population.
The two major aspects differentiating the management of
HTN in HD from the general population are the extremes of
extracellular fluid volume present in the majority of HD
patients who have lost their residual renal function and the
nature of dialysis. Short intense removal of fluid and the
impaired CV response in many patients to this result in
intradialytic hypotension, much dreaded by patients.
The role of combined sodium restriction together with use
of antihypertensive drugs has not been clarified. However,
given that patients in HD are usually in positive sodium
balance and would benefit from sodium restriction (inter-
and intradialytically), a combination of the latter plus drugs
may be the best practice. Randomized controlled trials on
HTN are rare in HD and should be encouraged. Long or
more frequent dialysis may solve the hemodynamic problems
associated with salt restriction and short dialysis time.
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